Progress in Neurotherapeutics and Neuropsychopharmacology
Volume 1, 2006
Herausgeber: Cummings, Jeffrey L.
Progress in Neurotherapeutics and Neuropsychopharmacology
Volume 1, 2006
Herausgeber: Cummings, Jeffrey L.
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
An essential update of clinical trials in the management of neurological and neuropsychiatric disorders.
Andere Kunden interessierten sich auch für
- Jeffrey L. Cummings (ed.)Progress in Neurotherapeutics and Neuropsychopharmacology48,99 €
- Jeffrey L. Cummings (ed.)Progress in Neurotherapeutics and Neuropsychopharmacology232,99 €
- Progress in Neurotherapeutics and Neuropsychopharmacology83,99 €
- Jeffrey L. Cummings (ed.)Progress in Neurotherapeutics and Neuropsychopharmacology201,99 €
- Progress In Psychobiology and Physiological Psychology241,99 €
- Gerald LangnerThe Neural Code of Pitch and Harmony116,99 €
- Harry M. MarksThe Progress of Experiment110,99 €
-
-
-
An essential update of clinical trials in the management of neurological and neuropsychiatric disorders.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Cambridge University Press
- Seitenzahl: 184
- Erscheinungstermin: 11. Juli 2012
- Englisch
- Abmessung: 244mm x 170mm x 10mm
- Gewicht: 329g
- ISBN-13: 9781107405875
- ISBN-10: 1107405874
- Artikelnr.: 35895738
- Verlag: Cambridge University Press
- Seitenzahl: 184
- Erscheinungstermin: 11. Juli 2012
- Englisch
- Abmessung: 244mm x 170mm x 10mm
- Gewicht: 329g
- ISBN-13: 9781107405875
- ISBN-10: 1107405874
- Artikelnr.: 35895738
Preface J. L. Cummings; Introduction to neurotherapeutics and
neuropharmacology J. L. Cummings; 1. Rivastigmine in the treatment of
dementia associated with Parkinson's disease: a randomized, double-blind,
placebo-controlled study S. Tekin and R. Lane; 2. Modafinil for the
treatment of fatigue in multiple sclerosis B. Stankoff, C. Lubetzki and M.
Clanet; 3. Radiotherapy with concurrent and adjuvant temozolomide: a new
standard of care for glioblastoma multiform W. P. Mason, R. O. Mirimanoff
and R Stupp; 4. Treating migraine attacks ASAP: concept and methodological
issues N. J. Wiendels and M. D. Ferrari; 5. Early phase trials of
minocycline in amyotropic lateral sclerosis P. H. Gordon, J. Choi, D. H.
Moore and R. G. Miller; 6. Creatine as a potential treatment for
amyotrophic lateral sclerosis J. M. Shefner; 7. AVP-923 as a novel
treatment for pseudobulbar affect ALS L. E. Pope; 8. Liquid fluoxetine vs.
placebo for repetitive behaviors in childhood autism E. Hollander, E.
Swanson, E. Anagnostou, A. Phillips, W. Chaplin and S. Wasserman; 9.
Testing multiple novel mechanisms for treating schizophrenia in a single
trial H. Y. Meltzer; 10. Selegiline in the treatment of negative symptoms
of schizophrenia A. Lin and A. Bodkin; 11. Analysis of the cognitive
enhancing effects of modafinil in schizophrenia D. C. Turner and B. J.
Sahakian; 12. Efficacy and tolerability of ziprasidone and olanzapine in
acutely ill inpatient with schizophrenia or schizoaffective disorder:
results of a double-blind, 6-week study, with a 6-month, double-blind,
continuation phase G. M. Simpson, A. Loebel, L. Warrington and R. Yang.
neuropharmacology J. L. Cummings; 1. Rivastigmine in the treatment of
dementia associated with Parkinson's disease: a randomized, double-blind,
placebo-controlled study S. Tekin and R. Lane; 2. Modafinil for the
treatment of fatigue in multiple sclerosis B. Stankoff, C. Lubetzki and M.
Clanet; 3. Radiotherapy with concurrent and adjuvant temozolomide: a new
standard of care for glioblastoma multiform W. P. Mason, R. O. Mirimanoff
and R Stupp; 4. Treating migraine attacks ASAP: concept and methodological
issues N. J. Wiendels and M. D. Ferrari; 5. Early phase trials of
minocycline in amyotropic lateral sclerosis P. H. Gordon, J. Choi, D. H.
Moore and R. G. Miller; 6. Creatine as a potential treatment for
amyotrophic lateral sclerosis J. M. Shefner; 7. AVP-923 as a novel
treatment for pseudobulbar affect ALS L. E. Pope; 8. Liquid fluoxetine vs.
placebo for repetitive behaviors in childhood autism E. Hollander, E.
Swanson, E. Anagnostou, A. Phillips, W. Chaplin and S. Wasserman; 9.
Testing multiple novel mechanisms for treating schizophrenia in a single
trial H. Y. Meltzer; 10. Selegiline in the treatment of negative symptoms
of schizophrenia A. Lin and A. Bodkin; 11. Analysis of the cognitive
enhancing effects of modafinil in schizophrenia D. C. Turner and B. J.
Sahakian; 12. Efficacy and tolerability of ziprasidone and olanzapine in
acutely ill inpatient with schizophrenia or schizoaffective disorder:
results of a double-blind, 6-week study, with a 6-month, double-blind,
continuation phase G. M. Simpson, A. Loebel, L. Warrington and R. Yang.
Preface J. L. Cummings; Introduction to neurotherapeutics and
neuropharmacology J. L. Cummings; 1. Rivastigmine in the treatment of
dementia associated with Parkinson's disease: a randomized, double-blind,
placebo-controlled study S. Tekin and R. Lane; 2. Modafinil for the
treatment of fatigue in multiple sclerosis B. Stankoff, C. Lubetzki and M.
Clanet; 3. Radiotherapy with concurrent and adjuvant temozolomide: a new
standard of care for glioblastoma multiform W. P. Mason, R. O. Mirimanoff
and R Stupp; 4. Treating migraine attacks ASAP: concept and methodological
issues N. J. Wiendels and M. D. Ferrari; 5. Early phase trials of
minocycline in amyotropic lateral sclerosis P. H. Gordon, J. Choi, D. H.
Moore and R. G. Miller; 6. Creatine as a potential treatment for
amyotrophic lateral sclerosis J. M. Shefner; 7. AVP-923 as a novel
treatment for pseudobulbar affect ALS L. E. Pope; 8. Liquid fluoxetine vs.
placebo for repetitive behaviors in childhood autism E. Hollander, E.
Swanson, E. Anagnostou, A. Phillips, W. Chaplin and S. Wasserman; 9.
Testing multiple novel mechanisms for treating schizophrenia in a single
trial H. Y. Meltzer; 10. Selegiline in the treatment of negative symptoms
of schizophrenia A. Lin and A. Bodkin; 11. Analysis of the cognitive
enhancing effects of modafinil in schizophrenia D. C. Turner and B. J.
Sahakian; 12. Efficacy and tolerability of ziprasidone and olanzapine in
acutely ill inpatient with schizophrenia or schizoaffective disorder:
results of a double-blind, 6-week study, with a 6-month, double-blind,
continuation phase G. M. Simpson, A. Loebel, L. Warrington and R. Yang.
neuropharmacology J. L. Cummings; 1. Rivastigmine in the treatment of
dementia associated with Parkinson's disease: a randomized, double-blind,
placebo-controlled study S. Tekin and R. Lane; 2. Modafinil for the
treatment of fatigue in multiple sclerosis B. Stankoff, C. Lubetzki and M.
Clanet; 3. Radiotherapy with concurrent and adjuvant temozolomide: a new
standard of care for glioblastoma multiform W. P. Mason, R. O. Mirimanoff
and R Stupp; 4. Treating migraine attacks ASAP: concept and methodological
issues N. J. Wiendels and M. D. Ferrari; 5. Early phase trials of
minocycline in amyotropic lateral sclerosis P. H. Gordon, J. Choi, D. H.
Moore and R. G. Miller; 6. Creatine as a potential treatment for
amyotrophic lateral sclerosis J. M. Shefner; 7. AVP-923 as a novel
treatment for pseudobulbar affect ALS L. E. Pope; 8. Liquid fluoxetine vs.
placebo for repetitive behaviors in childhood autism E. Hollander, E.
Swanson, E. Anagnostou, A. Phillips, W. Chaplin and S. Wasserman; 9.
Testing multiple novel mechanisms for treating schizophrenia in a single
trial H. Y. Meltzer; 10. Selegiline in the treatment of negative symptoms
of schizophrenia A. Lin and A. Bodkin; 11. Analysis of the cognitive
enhancing effects of modafinil in schizophrenia D. C. Turner and B. J.
Sahakian; 12. Efficacy and tolerability of ziprasidone and olanzapine in
acutely ill inpatient with schizophrenia or schizoaffective disorder:
results of a double-blind, 6-week study, with a 6-month, double-blind,
continuation phase G. M. Simpson, A. Loebel, L. Warrington and R. Yang.